EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals, Inc.

Overview
Date Founded

2004

Headquarters

271 Waverley Oaks Road,Suite 108,Waltham, MA 02452

Type of Company

Public

Employees (Worldwide)

14

Industries

Pharmaceuticals
Medical Support Services
Biotechnology
Medical Products & Equipment

Company Description

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Contact Data
Trying to get in touch with decision makers at EyeGate Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Executive Chairman

Chief Financial & Accounting Officer

Chief Commercial Officer

Vice President of Engineering

Vice President of R&D

Consulting Chief Medical Officer

Director

Director

Board of Directors

Executive Chairman at EyeGate Pharmaceuticals, Inc.

Chief Investment Officer at Armistice Capital LLC

Director at EyeGate Pharmaceuticals, Inc.

Chief Financial Officer, Treasurer & Executive Vice President at Avid Technology, Inc.

President & Chief Executive Officer at PanOptica, Inc.

Managing Director at Armistice Capital LLC

Former Vice President-Retina & Glaucoma at Ora, Inc.

Paths to EyeGate Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
EyeGate Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Recent Transactions
Details Hidden

EyeGate Pharmaceuticals, Inc. purchases Panoptes Pharma GmbH

Details Hidden

EyeGate Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

EyeGate Pharmaceuticals, Inc. raised money in a private placement transaction

Transaction Advisors
Underwriter

Advised onEyeGate Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onEyeGate Pharmaceuticals, Inc. issued USD Common Stock

Auditor

Advised onEyeGate Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onEyeGate Pharmaceuticals, Inc. purchases Jade Therapeutics, Inc.

Advisors & Consultants
Legal Advisor

Partner at Morgan, Lewis & Bockius LLP

Legal Advisor

Partner, Co-Chair, Intellectual Property at Burns & Levinson LLP

Consultant

Co-Founder & Chief Medical Officer at Qlaris Bio, Inc.

Clients

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Key Stats and Financials As of 2020
Market Capitalization
$32M
Total Enterprise Value
$21.7M
Earnings Per Share
$-1.77
Net Profit
$-8.09M
EBITDA
$-8.01M
EBITDAMargin
-66.4K%
Total Debt
$362K
Total Equity
$7M
Enterprise Value / Sales
1,802.51x
TEVNet Income
-2.69x
Debt TEV
0.02x
Revenue
$12.1K
Investors
Details Hidden

Medicis is an active manager which invests in and provides strategic advice to companies in the healthcare industry, focusing on the pharmaceutical, medtech and healthcare services (including care delivery facilities) sectors. Typical transactions include providing growth capital to proven businesses as well as small- to mid-sized buy-outs.The firm aims to provide their market expertise and financial and business network to young, innovative companies employing cutting edge life science technologies or novel health management concepts and/or systems. They partner with their investee companies, aiming to improve the quality and efficiency of the life science and healthcare market.Medicis leads or co-lead investments, supporting the commercialization of products and the development of research approaches to marketable products.

Details Hidden

Founder at Eyevensys SAS

Details Hidden

Co-Founder at IVERIC bio, Inc.

Suppliers
Lineage Cell Therapeutics, Inc. Medical Support Services | Alameda, CA

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

SentrX Animal Care, Inc. Industrial Machinery & Manufacturing | Salt Lake City, UT

SentrX Animal Care, Inc. provides veterinary care services for animals. Its products include gels, film and field treatment kits, film-on-gauzes, adhesion prevention films, spray bottles, and corneal repair gel drops. The company’s products are used for horses, cats and dogs. The company was founded by Richard K. Koehn and Glenn D. Prestwich in 2006 and is headquartered in Salt Lake City, UT.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by EyeGate Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of EyeGate Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and EyeGate Pharmaceuticals, Inc..